Search Results

Displaying Results 1851-1875 of 2003 "'LUNG'"

Oct 13, 2025, 12:53 ET Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.  

More news about: Nuvalent, Inc.


Oct 13, 2025, 12:10 ET Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

over $5.9 billion in 2024, highlighting a significant unmet need. Lung cancer is the leading cause of cancer deaths and there are there are over 200,000 new cases expected in the U.S. in 2025. NSCLC accounts for approximately 85% of all lung cancer cases. The EGFR TKI Osimertinib (TAGRISSO, AstraZeneca)

More news about: Actinium Pharmaceuticals, Inc.


Oct 13, 2025, 10:57 ET U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer. Increased risk of major cardiovascular events such as heart attack, stroke, or death

More news about: AbbVie


Oct 13, 2025, 09:00 ET GC Biopharma Highlights IVIG Innovation and Investigator-Initiated Research as Science to Solutions Partner at the Fall 2025 CIIC Conference

particularly patients with risk factors. Transfusion-Related Acute Lung Injury: Noncardiogenic pulmonary edema (transfusion-related acute lung injury [TRALI]) may occur. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal

More news about: GC Biopharma USA Inc.


Oct 13, 2025, 08:43 ET AccuGenomics and 1Cell.Ai Partner to Bring Ultra-Sensitive Liquid Biopsy Testing Across Asia, with Plans for U.S. Expansion

controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding internal standards within every patient sample tested, laboratories can confirm per-sample analytical accuracy, improve

More news about: AccuGenomics


Oct 13, 2025, 08:30 ET IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications.

More news about: IceCure Medical


Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

presentation and diagnosis of lung cancer: a systematic review. BMC Cancer. 2019; 19, 25. doi:10.1186/s12885-018-5169-9 Shalata W, Naamneh R, Najjar W, et al. Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. Med Sci.

More news about: AbbVie


Oct 13, 2025, 06:45 ET Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

showcase Lilly's robust oncology pipeline with data from studies of investigational therapies targeting FRα positive ovarian cancer, KRAS G12C-mutant lung cancer, FGFR3-altered bladder cancer, and PIK3CA-mutant advanced breast cancer

More news about: Eli Lilly and Company


Oct 13, 2025, 05:00 ET SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

ADC portfolio." Iza-bren is currently being evaluated in multiple ongoing clinical trials, including BL-B01D1-LUNG-101 (NCT05983432), IZABRIGHT-Lung01 (NCT07100080), IZABRIGHT-Bladder01 (NCT07106762), and studies in China conducted by Biokin. The program recently received Breakthrough

More news about: SystImmune, Inc.


Oct 12, 2025, 18:27 ET Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

Treatment-related adverse events of grade 3 or higher occurred in 8 patients (25%) and included anemia (n=3) and interstitial lung disease (n=2). There was one death due to interstitial lung disease. About REZILIENT2REZILIENT2 is a Phase 2b clinical trial

More news about: Taiho Oncology


Oct 12, 2025, 16:47 ET SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit

lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the MOLBREEVI (a clinical trial for the treatment of a rare lung disease) Biologics License Application ("BLA") lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (2) accordingly,

More news about: THE ROSEN LAW FIRM, P. A.


Oct 10, 2025, 18:51 ET South Coast AQMD Issues Violations to Two Paramount Facilities Following Investigation of Slightly Elevated Hexavalent Chromium Levels

Hexavalent chromium is a toxic air contaminant and a known human carcinogen. Long-term exposure over many years can increase the risk of lung cancer. Background South Coast AQMD began air monitoring in

More news about: SOUTH COAST AQMD


Oct 10, 2025, 09:00 ET Thyme Care and American Oncology Network (AON) Present Nine Research Abstracts at ASCO Quality 2025, Showcasing Leadership in Value-Based Cancer Care Design and Delivery

#87)Evaluating the Explanatory Power of Histology as a Clinical Adjuster in EOM Lung Cancer Episodes. Shows that histology adds minimal explanatory value to benchmark variation in lung cancer, questioning its utility in reporting. (

More news about: Thyme Care


Oct 09, 2025, 17:31 ET Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight

Ovarian cancer accounts for only about 3% of cancers in women but stands as the fifth leading cause of cancer-related deaths, following lung, breast, colorectal, and pancreatic cancers. It can arise from various ovarian cell types, including the epithelial cells that line the ovary, germ cells

More news about: DelveInsight Business Research, LLP


Oct 09, 2025, 14:00 ET WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

The Company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes. The common stock described above was offered by the Company pursuant to

More news about: WallachBeth Capital LLC


Oct 09, 2025, 11:10 ET Endoscopy Procedures Market to Reach $617.8 billion, Globally, by 2034 at 5.5% CAGR: Allied Market Research

pulmonology approach for the detection and treatment of lung cancer. Stanford Health Care is pioneering the use of robotic bronchoscopy combined with cone beam CT (CBCT) guidance to improve the diagnosis and treatment of lung cancer. Traditional methods for lung nodule biopsies, such as flexible bronchoscopy

More news about: Allied Market Research


Oct 09, 2025, 10:30 ET ECMO Machine Market worth US$0.86 billion by 2030 with 5.8% CAGR | MarketsandMarkets™

share in the ECMO machines market. Adults are disproportionately affected by lifestyle-induced disorders such as obesity, diabetes, smoking-related lung disease, and hypertension. These conditions often lead to severe cardiovascular or pulmonary complications. Obesity and diabetes, for example, are strong

More news about: MarketsandMarkets


Oct 09, 2025, 08:36 ET Summit Cancer Center Director, Arvind Chaudhry, MD, PhD, to Chair Coeur d'Alene Hematology Oncology Conference Focused on Precision-Guided Cancer Care

radiation oncologists, and surgical oncologists—involved, almost like a tumor board format." Dr. Chaudhry will also chair the lung cancer session, a timely focus as the field continues to evolve with a surge of FDA approvals for targeted and immune therapies. "It

More news about: Summit Cancer Centers


Oct 09, 2025, 08:30 ET Oncology Leaders Champion Innovation and Collaboration To Advance Cancer Care

application of new data and recent medical research for the treatment of a wide range of cancers, ranging from HR-positive breast and prostate cancers to lung cancer, lymphomas, and other blood diseases. Keynote speakers for the 2025 FCS Clinical Summit are Liza Marshall, a breast cancer

More news about: Florida Cancer Specialists & Research Institute


Oct 09, 2025, 08:30 ET IceCure Medical to Attend the 2025 Maxim Growth Summit

cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure.

More news about: IceCure Medical


Oct 09, 2025, 06:30 ET Best Posture Support and Back Care for Scoliosis (2025): Forme® Awarded for Improving in Real Time Alignment, Mobility & Comfort by Expert Consumers

of any age. Symptoms vary, but they often include uneven shoulders or hips, rib cage rotation, chronic back pain, and reduced lung capacity. Severe cases can lead to mobility challenges and long-term musculoskeletal issues. About 80 percent of pediatric cases are idiopathic, meaning

More news about: ExpertConsumers.org


Oct 09, 2025, 06:23 ET GlyTR Therapeutics announces landmark study in Cell on their 'Velcro-like' Pan-Cancer Immunotherapy Platform

Demonstrates potent, selective killing of multiple highly diverse tumors in preclinical models, including breast, ovarian, colon, pancreatic, lung, prostate and leukemia. Shows no toxicity in mice with human-like glycan expression. Details

More news about: GlyTR Therapeutics


Oct 09, 2025, 05:30 ET Best Back Pain Relief and Support Wear (2025): Forme® Smart Clothing Awarded Top Solution For Real Time Pain Relief by Expert Consumers

Why Posture Matters Poor posture is more than a cosmetic concern. It can contribute to headaches, reduced lung capacity, poor digestion, muscle strain, immobility, and chronic pain. Socially, posture conveys confidence and presence, influencing perception in

More news about: ExpertConsumers.org


Oct 09, 2025, 05:11 ET Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87

diversified product pipeline. Its proprietary spray drying platform enables the transformation of biological macromolecules, low-activity drugs, and deep lung/systemic delivery drugs into highly efficient dry powder inhalation formulations. The company's modern manufacturing facility,

More news about: Chance Pharmaceuticals


Oct 09, 2025, 03:30 ET Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025

to expand the potential of its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting 

More news about: Resolution Therapeutics


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.